Top-News

Nektar Therapeutics Aktie News

Aktie
WKN:  A419UB ISIN:  US6402683063 US-Symbol:  NKTR Branche:  Pharmazeutika Land:  USA
56,605 $
-1,085 $
-1,88%
48,623 € 20:50:45 Uhr
Depot/Watchlist
Marktkapitalisierung *
9,08 Mrd. €
Streubesitz
31,57%
KGV
-
Index-Zuordnung
-

Nektar Therapeutics News

08.05.25 - PR Newswire
Nektar Therapeutics Reports First Quarter 2025 Financial Results
Nektar Therapeutics Reports First Quarter 2025 Financial Results PR Newswire
01.05.25 - PR Newswire
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets PR Newswire
20.03.25 - PR Newswire
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire
12.03.25 - PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results PR Newswire
05.03.25 - PR Newswire
Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
Nektar to Announce Financial Results for the Fourth Quarter and Year-​Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets PR Newswire
26.02.25 - PR Newswire
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-​AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-​to-Very Severe Alopecia ...
24.02.25 - PR Newswire
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th PR Newswire
24.02.25 - PR Newswire
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus PR Newswire
10.02.25 - PR Newswire
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-​to-Severe Atopic Dermatitis PR Newswire
10.01.25 - PR Newswire
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-​AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-​to-Severe Atopic ...
07.12.24 - PR Newswire
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell ...

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »